Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: friend or foe ?
CoronaVirus Disease-19 (COVID-19) poses a threat to individuals with chronic health conditions who are more likely to develop severe pneumonia and death. Those with pulmonary arterial hypertension represent such a high-risk group. Severe COVID-19 presents with respiratory failure secondary to immuno-pathologic injury likely due to a combination of direct cytopathic effects of the virus in concert with an aberrant immune response. The interplay between these two components has been recently better understood.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Roberto Badagliacca, Susanna Sciomer, Nicola Petrosillo Tags: Case Anecdotes, Comments and Opinions Source Type: research
More News: Cardiology | Coronavirus | COVID-19 | Heart | Heart Transplant | Hypertension | Lung Transplant | Pneumonia | Respiratory Medicine | Transplant Surgery | Transplants